The agreement, terms of which were not disclosed, is a multi-year venture that will operate on a global scale.
Tal Rosenberg, Senior Vice President, Technology Solutions, QuintilesIMS told us the company is building new solutions to complement its existing ones, “taking advantage of [Salesforces’] built-in cloud, mobile, social and artificial intelligence capabilities,” he said.
By building apps on the Salesforce Platform, which is updated three times a year, Rosenberg said QuintilesIMS can focus on its areas of differentiation.
“These applications will help life science companies drive patient recruitment, manage clinical trials, marketing and other key activities as they bring new therapies to market,” he explained, adding that the company will initially work with Salesforce on apps in these areas.
Long term, QuintilesIMS will work with Salesforce in new areas, such as digital health, precision medicine and patient engagement, by leveraging artificial intelligence (AI) and Internet of Things (IoT) technologies as part of the Salesforce Platform.
“The partnership will ultimately help customers bring new therapies to market faster and more efficiently – taking advantage of the latest in cloud, mobile, social and artificial intelligence technologies,” said Rosenberg.
“This alliance has transformative potential for the life sciences industry, as it will better equip and enable our mutual customers to meet the challenges they face as they move healthcare forward.”